Cipher Pharmaceuticals Announces Results of Annual and Special Meeting of Shareholders and Thanks Director Dr. John Mull

MISSISSAUGA, ON, June 22, 2022 /CNW/ – Cipher Pharmaceuticals Inc. (TSX: CPH) (“Encrypt“or the”Company“) announced today that it held its annual and special meeting of shareholders earlier today and that all matters submitted for the consideration and approval of shareholders, as set out in the information circular of the management of the Company dated May 13, 2022 were approved by the required majority of votes cast at the meeting. In particular, the shareholders approved the election of all director nominees, the re-approval of Ernst & Young LLP as the Company’s auditors and the approval of unallocated shares, rights and other rights in under the Company’s stock purchase plan. A total of 14.2 million shares, representing 55.9% of the total shares outstanding, were represented in person or by proxy at the meeting. The Board of Directors (the “Board”) of the Company is now composed as follows:


% of shares voted

% of shares retained

Craig Mull



Harold Wolkin



Christian Godin



Arthur Deboeck



Cathy Steiner



Company founder and longtime director, Dr. John Mull decided not to stand again on the Board of Directors of the Company.

Craig Mullinterim CEO commented, “As founder and former CEO of Cipher, Dr. Mull has been instrumental in the growth of the company. During his tenure, Dr. Mull has contributed to the development and played a critical role in obtaining FDA and Health Canada approval for three products, including Cipher’s isorentinoin portfolio Under his leadership, Cipher developed some of the leading acne products in North America. Dr. Mull also played a key role in capitalizing the company, which set it on the path to success. On behalf of the Board of Directors, I would like to thank him for his years of service and wish him well in his real estate development venture and other future endeavours. »

“It has been extremely gratifying to witness and be part of Cipher’s evolution since its separation from CML Healthcare in 2004. Today, the company has a stable foundation with strong distribution and support agreements. sourcing in place in addition to a disciplined cost structure – positioning it well to continue to accelerate growth and generate shareholder value.As a significant shareholder of the Company, I look forward to following the future development of the Society.” it is noted dr. John Mull.

Final voting results for all matters to be voted on at the Meeting will be available on SEDAR at

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals (TSX: CPH) is a specialty pharmaceutical company with a strong and diverse portfolio of commercial and early-to-late-stage products. Cipher acquires products that address unmet medical needs, manages the required clinical development and regulatory approval process, and currently commercializes these products either directly in Canada or indirectly through partners in Canada, the United States United and South America. For more information, visit

Forward-looking statements

This document contains forward-looking statements within the meaning of applicable securities laws. These forward-looking statements include, among other things, statements regarding the future of the Company’s business as well as statements regarding our beliefs, plans, expectations, anticipations, estimates and intentions. The words “may”, “will”, “could”, “should”, “remember”, “outlook”, “believe”, “plan”, “anticipate”, “estimate”, “expect”, ” intend”, “plan”, “objective”, “hope” and “continue” (or their negative form), and words and expressions of similar prominence, are intended to identify forward-looking statements.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, which give rise to the possibility that the predictions, forecasts, projections and other forward-looking statements will not be achieved. Certain important factors or assumptions are applied to make forward-looking statements and actual results may differ materially from those expressed or implied by such statements. We caution readers not to place undue reliance on these statements because a number of important factors, many of which are beyond our control, could cause our actual results to differ materially from beliefs, plans, objectives, expectations, anticipations, estimates and intentions expressed. in such forward-looking statements. These factors include, but are not limited to, the extent and impact of the coronavirus (COVID-19) outbreak on our business, including any impact on our contractors and other third-party service providers, our ability to enter into development, manufacturing and marketing and distribution agreements with other pharmaceutical companies and maintain such agreements in effect; our dependence on a limited number of products; our reliance on patent protection that will expire; integration difficulties and other risks if we acquire or license technology or product candidates; the use of third parties for the marketing of certain products; the product approval process is highly unpredictable; the timing of the completion of clinical trials, regulatory submissions and regulatory approvals; reliance on third parties to manufacture our products and events beyond our control that could adversely impact the ability of our manufacturing partners to provide products that meet our demands; we may be subject to future product liability claims; unexpected issues with the safety or effectiveness of the product may arise; we generate licensing revenue from a limited number of distribution and supply agreements; the pharmaceutical industry is highly competitive; additional capital requirements to fund future operations; products in Canada may be subject to price regulation; dependence on key management personnel and external collaborators; no guarantee that we will receive regulatory approvals in the United States, Canada or any other jurisdiction and the current uncertainty surrounding health care regulation in the United States; some of our products are regulated as controlled substances; reimbursement limits in the healthcare sector; limited reimbursement of products by governmental authorities and third-party payment policies; the products may not be on the list of drugs approved for use in hospitals; hospital customers may make late payments or fail to make payments; various health care fraud and abuse laws; confidence in the success of strategic investments and partnerships; the publication of negative results of clinical trials; unpredictable development goals and projected timelines; increased insurance costs; ability to enforce non-competition clauses; risks associated with the industry in which we operate; we may fail to assess the material risks associated with completed and future acquisitions; we may be unable to successfully identify, acquire or integrate acquisition targets; risks inherited from operations in the United States; compliance with confidentiality and security rules; our policies regarding returns, allowances and chargebacks may reduce revenue; certain current and future regulations could restrict our activities; regulatory burden and additional controls over financial reporting; the use of third parties to perform certain services; general commercial litigation, class actions, other contentious claims and regulatory actions; the difficulty for shareholders to realize in United States on the judgments of the United States courts based on the civil liability of the Company and its directors and officers who are not residents of United States; potential infringement of third party intellectual property rights; our efforts to obtain, protect or enforce our patents and other intellectual property rights relating to our products; changes in US, Canadian or foreign patent laws; litigation in the pharmaceutical industry regarding the manufacture and supply of new and generic versions of existing drugs; failure to protect our brands against infringement; shareholders may be further diluted if we issue securities to raise capital; the volatility of our stock price; the fact that we have a major shareholder; we do not currently intend to pay any dividends; our operating results may fluctuate significantly; and our debt securities will have priority over the common shares of the Company in the event of liquidation, dissolution or liquidation.

We draw your attention to the fact that the foregoing list of important factors that could affect future results is not exhaustive. When reviewing our forward-looking statements, investors and others should carefully consider the foregoing factors as well as other uncertainties and potential events. Additional information about factors that could cause actual results to differ materially from expectations, as well as important factors or assumptions applied in making forward-looking statements, can be found in the “Risk Factors” section of the notice. annual report of the Company for the financial year ended December 31, 2021, and elsewhere in our filings with Canadian securities regulators. Except as required by Canadian securities law, we do not undertake to update any forward-looking statements, written or oral, which may be made from time to time by us or on our behalf; these statements speak only as of the date on which they were made. The forward-looking statements included herein are expressly qualified in their entirety by this cautionary statement.

SOURCE Cipher Pharmaceuticals Inc.

For further information: James Bowen, CFA, Investor Relations, Cipher Pharmaceuticals, 416-519-9442, [email protected]

Comments are closed.